Trials / Recruiting
RecruitingNCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 147 (estimated)
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986393 | Specified dose on specified days |
| DRUG | Alnuctamab | Specified dose on specified days |
| DRUG | Mezigdomide | Specified dose on specified days |
| DRUG | Iberdomide | Specified dose on specified days |
| DRUG | Elranatamab | Specified dose on specified days |
Timeline
- Start date
- 2024-02-22
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
- First posted
- 2023-11-08
- Last updated
- 2026-02-18
Locations
19 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06121843. Inclusion in this directory is not an endorsement.